Conference Coverage

VIDEO: Dr. Ann Partridge discusses counseling young breast cancer patients


 

EXPERT ANALYSIS FROM MBCC

References

MIAMI BEACH – Despite significant improvements in detection and treatment of contralateral breast cancer, there’s a “huge increase” in the number of women choosing to undergo bilateral mastectomy, Dr. Ann Partridge of Dana-Farber Cancer Institute in Boston said.

Physicians can counsel patients that the risk of cancer recurrence in the body elsewhere is more of a concern than a new breast cancer, Dr. Partridge said, and provide a realistic picture of the side effects and potential complications of bilateral versus unilateral surgery. Conversations between physicians and patients regarding the pros and cons of more aggressive therapy are essential, she said in a video interview at the annual Miami Breast Cancer Conference, held by Physicians’ Education Resource.

Some ethical considerations arise when counseling younger women with a genetic mutation that raises the risk of breast cancer (for example, BRCA1 or BRCA2), especially when they plan to undergo in vitro fertilization and pre-implantation embryo analysis. Dr. Partridge shares advice on how to help these women make the best decision for them.

Many women diagnosed with breast cancer before age 40 wonder if it’s safe to have a baby, Dr. Partridge said. Ask about intentions to get pregnant at the first visit, she advised, and share data from retrospective outcome comparisons when guiding these women on their options.

Dr. Partridge had no relevant financial disclosures.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

A Perfect Storm: Patterns of care
MDedge Hematology and Oncology
Prevention driving increase in mastectomies
MDedge Hematology and Oncology
Prospective study confirms chemo not needed after low Recurrence Score
MDedge Hematology and Oncology
Daily updates from the Miami Breast Cancer Conference begin March 11
MDedge Hematology and Oncology
FDA approves fulvestrant for use in combination with palbociclib
MDedge Hematology and Oncology
Ultrasound bested tomosynthesis for screening dense breast tissue
MDedge Hematology and Oncology
VIDEO: Focused breast cancer radiation maintains efficacy, cuts AEs
MDedge Hematology and Oncology
Neoadjuvant chemo reduces extent of axillary dissection in some breast cancers
MDedge Hematology and Oncology
Stop using radiation therapy in older women, expert says
MDedge Hematology and Oncology
VIDEO: Physicians must counsel women on mastectomy misperceptions
MDedge Hematology and Oncology